Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last kr2.90 DKK
Change Today -0.02 / -0.68%
Volume 1.2M
As of 10:59 AM 05/29/15 All times are local (Market data is delayed by at least 15 minutes).

bioporto a/s (BIOPOR) Snapshot

Open
kr3.00
Previous Close
kr2.92
Day High
kr3.09
Day Low
kr2.88
52 Week High
05/28/15 - kr3.24
52 Week Low
10/16/14 - kr1.35
Market Cap
341.8M
Average Volume 10 Days
1.7M
EPS TTM
kr-0.11
Shares Outstanding
117.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIOPORTO A/S (BIOPOR)

Related News

No related news articles were found.

bioporto a/s (BIOPOR) Related Businessweek News

No Related Businessweek News Found

bioporto a/s (BIOPOR) Details

BioPorto A/S, an in-vitro diagnostics company, develops and markets diagnostic tests and antibodies for the healthcare professionals in clinical and research settings. Its products include neutrophil gelatinase-associated lipocalin (NGAL) Test for the diagnosis of acute kidney injury; and NGAL enzyme-linked immunosorbent assay (ELISA) kit for the in vitro determination of human NGAL in urine, plasma, serum, tissue extracts, or culture media. The company also provides activated protein C and protein C inhibitor complex (APC-PCI) ELISA kit that measures the APC-PCI in human plasma for the treatment of sepsis; and mannan-binding lectin (MBL) oligomer ELISA kit to determine oligomerized MBL in human serum or heparin plasma for the assessment of primary immunodeficiency. In addition, it markets various monoclonal antibodies under the AntibodyShop name, including antibodies for the research in the areas of NGAL; peptide hormones, including type-2 diabetes/obesity; immunology; and microbiology. The company was founded in 2000 and is based in Gentofte, Denmark.

26 Employees
Last Reported Date: 05/5/15
Founded in 2000

bioporto a/s (BIOPOR) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

bioporto a/s (BIOPOR) Key Developments

BioPorto A/S Reports Earnings Results for the First Quarter of 2015; Maintains Earnings Guidance for the Full Year of 2015

BioPorto A/S reported earnings results for the first quarter of 2015. BioPorto generated revenue of DKK 4.1 million in first quarter 2015, against DKK 4.8 million in the year-earlier period, when revenue was positively affected by license income from Abbott. Net of this income, revenue was up by approximately 14% compared with first quarter 2014. EBIT was a loss of DKK 4.4 million against a loss of DKK 3.6 million in 2014, and the loss for the period was DKK 4.0 million against a loss of DKK 3.6 million in 2014. Loss before tax was DKK 4.487 million against DKK 3.612 million a year ago. Cash flow from operations was DKK 3.410 million against DKK 5.414 million a year ago. Negative return on equity was 15% against 9% a year ago. Loss per share (lps/dps) was DKK 0.03 against DKK 0.03 loss per share a year ago. Purchase of tangible assets was DKK 0.033 million against DKK 0.361 million a year ago. The company maintained earnings guidance for the full year of 2015. Revenue is expected to be DKK 22 million to DKK 25 million in 2015, representing an increase of approximately 15%-35% on 2014. EBIT for 2015 is forecast at a loss between DKK 10 million and DKK 12 million, and it expects a net loss at the level of DKK 8 million to DKK 10 million, which would be a notable improvement on 2014.

BioPorto A/S, Q1 2015 Earnings Call, May 05, 2015

BioPorto A/S, Q1 2015 Earnings Call, May 05, 2015

BioPorto A/S Approves the Election of Jan Kuhlmann Andersen as a New Board Member

BioPorto A/S held its Annual General Meeting on April 10, 2015, the shareholders approved the election of Jan Kuhlmann Andersen as a new board member.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIOPOR:DC kr2.90 DKK -0.02

BIOPOR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bavarian Nordic A/S kr336.50 DKK +3.00
Chimerix Inc $41.85 USD +0.24
Emergent Biosolutions Inc $31.86 USD +0.11
GlaxoSmithKline PLC 1,454 GBp -6.50
View Industry Companies
 

Industry Analysis

BIOPOR

Industry Average

Valuation BIOPOR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 19.3x
Price/Book 14.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 18.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOPORTO A/S, please visit www.bioporto.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.